2nd Circ. Ruling Presents Risks For Drug Cos. In Litigation

By Greg Ryan (December 4, 2012, 11:01 PM EST) -- Drugmakers that promote their products for off-label uses following the Second Circuit's landmark ruling on Monday could find themselves without their go-to defense in some personal injury lawsuits, attorneys say, since securing preemption when the use of a drug is not federally approved will likely prove a formidable task....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!